Preclinical
Researchers at the University of Illinois at Chicago have uncovered the possibility of utilizing gene editing to reverse a cause of anxiety and alcohol use disorder (AUD).
Context Therapeutics’ lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
Dianthus Therapeutics launched today with $100 million in Series A financing led by 5AM Ventures, Avidity Partners and Fidelity Research and Management. The company plans to tackle severe and rare autoimmune diseases by utilizing antibodies that target complements.
What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules. The company has 14 small molecule drugs in development.
Bryostatin-1 increases antigen expression on the surface of cancer cells, enabling them to be seen and killed by IO agents.
AviadoBio is celebrating orphan drug designations from both the U.S. FDA and the European Commission for AVB-101, a gene therapy intended to treat frontotemporal dementia (FTD).
Pheast Therapeutics launched today with $76 million in Series A financing. Pheast is focused on developing cancer checkpoint therapies to fight malignant cells, focusing on ovarian and breast cancers.
Eliem Therapeutics could be in trouble following the announcement that its drug candidate ETX-810, intended to treat diabetic peripheral neuropathic pain, did not meet its primary endpoint.
Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.
Heat Biologics announced a new development underway in its partnership with Scorpion Biological Services to develop a manufacturing facility in Manhattan, Kansas.
PRESS RELEASES